Bisubstrate-Type Chemical Probes Identify GRP94 as a Potential Target of Cytosine-Containing Adenosine Analogs.
Journal
ACS chemical biology
ISSN: 1554-8937
Titre abrégé: ACS Chem Biol
Pays: United States
ID NLM: 101282906
Informations de publication
Date de publication:
17 04 2020
17 04 2020
Historique:
pubmed:
20
3
2020
medline:
23
1
2021
entrez:
20
3
2020
Statut:
ppublish
Résumé
We synthesized affinity-based chemical probes of cytosine-adenosine bisubstrate analogs and identified several potential targets by proteomic analysis. The validation of the proteomic analysis identified the chemical probe as a specific inhibitor of glucose-regulated protein 94 (GRP94), a potential drug target for several types of cancers. Therefore, as a result of the use of bisubstrate-type chemical probes and a chemical-biology methodology, this work opens the way to the development of a new family of GRP94 inhibitors that could potentially be of therapeutic interest.
Identifiants
pubmed: 32191434
doi: 10.1021/acschembio.9b00965
pmc: PMC7336334
mid: NIHMS1593591
doi:
Substances chimiques
Affinity Labels
0
Membrane Glycoproteins
0
Proteome
0
endoplasmin
0
Cytosine
8J337D1HZY
Adenosine
K72T3FS567
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
952-961Subventions
Organisme : NCI NIH HHS
ID : P01 CA186866
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Références
Angew Chem Int Ed Engl. 2009;48(38):6974-98
pubmed: 19714693
Tumour Biol. 2016 Jun;37(6):8219-27
pubmed: 26718209
Biochim Biophys Acta. 2012 Mar;1823(3):774-87
pubmed: 22079671
Curr Drug Targets. 2020;21(3):302-317
pubmed: 31465284
J Med Chem. 2013 Sep 12;56(17):6803-18
pubmed: 23965125
BMC Res Notes. 2012 Jan 12;5:25
pubmed: 22240105
Nat Rev Cancer. 2018 Sep;18(9):562-575
pubmed: 29795326
Cancer Cell. 2019 Nov 11;36(5):559-573.e7
pubmed: 31668946
PLoS One. 2015 Jun 12;10(6):e0129848
pubmed: 26070193
Cell Chem Biol. 2016 Jan 21;23(1):158-172
pubmed: 26933742
Cancer Invest. 2009 May;27(4):453-8
pubmed: 19212831
Nat Med. 2018 Aug;24(8):1157-1166
pubmed: 30038221
Nat Chem Biol. 2013 Nov;9(11):677-84
pubmed: 23995768
J Biol Chem. 2003 Nov 28;278(48):48330-8
pubmed: 12970348
J Med Chem. 2017 Jun 8;60(11):4665-4679
pubmed: 28463515
J Biomol Screen. 2004 Aug;9(5):375-81
pubmed: 15296636
J Biol Chem. 1996 Mar 1;271(9):4974-7
pubmed: 8617772
Biomed Pharmacother. 2018 Sep;105:115-120
pubmed: 29852388
Bioorg Med Chem Lett. 2006 Sep 1;16(17):4515-8
pubmed: 16797988
J Biol Chem. 2002 Jan 4;277(1):395-401
pubmed: 11689555
Nat Rev Cancer. 2014 Apr;14(4):263-76
pubmed: 24658275
Cancer Biol Ther. 2006 Jul;5(7):741-4
pubmed: 16861902
Mol Genet Metab. 2017 Dec;122(4):145-152
pubmed: 29033250
J Am Chem Soc. 2012 Jun 13;134(23):9796-804
pubmed: 22642269
J Med Chem. 2006 Jan 12;49(1):381-90
pubmed: 16392823
Mol Endocrinol. 1999 Sep;13(9):1435-48
pubmed: 10478836
Leukemia. 2020 Jan;34(1):50-62
pubmed: 31201358
Bioorg Med Chem. 2011 Apr 15;19(8):2603-14
pubmed: 21459002
J Heterocycl Chem. 2005;42(4):557-562
pubmed: 16467919
Philos Trans R Soc Lond B Biol Sci. 2018 Jun 5;373(1748):
pubmed: 29685976
Nat Commun. 2018 Oct 19;9(1):4345
pubmed: 30341316
Org Biomol Chem. 2003 Jan 7;1(1):42-9
pubmed: 12929389
J Med Chem. 2015 May 14;58(9):3922-43
pubmed: 25901531
Clin Epigenetics. 2016 Jul 18;8:76
pubmed: 27437033
Oncotarget. 2015 Dec 29;6(42):44254-73
pubmed: 26497551
Oncotarget. 2016 Nov 8;7(45):72923-72940
pubmed: 27662661
J Biol Chem. 2019 Nov 1;294(44):16010-16019
pubmed: 31501246
Tumour Biol. 2016 Jun;37(6):8121-30
pubmed: 26715271
Biochem Biophys Res Commun. 2015 Oct 23;466(3):481-5
pubmed: 26367179
Nature. 2016 Oct 20;538(7625):397-401
pubmed: 27706135
Cold Spring Harb Perspect Biol. 2020 Apr 1;12(4):
pubmed: 30936118
J Med Chem. 2005 Jan 13;48(1):321-9
pubmed: 15634027